Eledon Pharmaceuticals Inc. Common Stock (ELDN)
Stock · NASDAQ · Health Care
$2.13as of 10/16/2026
Price chart
Active signals
ELDN Signal Track Record
How signals performed across all stocks →What ELDN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 51 | -1.1% | 47% | September 1, 2026 |
| Bollinger Band BreakdownActive now | 22 | +5.4% | 59% | August 28, 2026 |
| Bollinger Band Breakout | 22 | +2.2% | 64% | April 16, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -20.2% | 0% | September 3, 2026 |
| Any 20-session window (baseline) | -0.3% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ELDN
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biologi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 33
- Website
- eledon.com/
Fundamentals
- 1-day range
- $2.16$2.42
- Market cap
- $267.07M
- P/E (trailing)
- —
- P/E (forward)
- -2.81
- EPS (trailing)
- $-0.96
- Dividend yield
- —
- Beta
- 1.01
- Avg. volume
- 914.1K
- Dividend pay date
- October 5, 2020
Forecasts
5 analyst ratings
Eledon Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ELDNEledon Pharmaceuticals Inc. Common Stock$2.13▼ 6.17%Market cap $267.07MP/E —$1.35$4.6
- TRDAEntrada Therapeutics Inc. Common Stock$4.37▼ 8.58%Market cap $266.70MP/E —$4.11$16.45
- PRQRProQR Therapeutics N.V. Ordinary Shares$1.31▼ 9.66%Market cap $268.13MP/E —$1.33$3.1
- CLLSCellectis S.A. American Depositary Shares$1.04▼ 5.88%Market cap $270.42MP/E —$1.04$4.75
- VRXAVeraxa Biotech AG Ordinary Shares$1.11▲ 0.91%Market cap $263.02MP/E —$1.04$27.36
- ADAGAdagene Inc. American Depositary Shares$2.06▼ 14.17%Market cap $273.45MP/E —$1.3$4.85
- EBSEmergent BioSolutions Inc. Common Stock$6.38▼ 11.14%Market cap $273.98MP/E —$4.36$14.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ELDN Eledon Pharmaceuticals Inc. Common Stock | $267.07M | — | $2.13 | ▼ 6.17% | $1.35$4.6 |
| TRDA Entrada Therapeutics Inc. Common Stock | $266.70M | — | $4.37 | ▼ 8.58% | $4.11$16.45 |
| PRQR ProQR Therapeutics N.V. Ordinary Shares | $268.13M | — | $1.31 | ▼ 9.66% | $1.33$3.1 |
| CLLS Cellectis S.A. American Depositary Shares | $270.42M | — | $1.04 | ▼ 5.88% | $1.04$4.75 |
| VRXA Veraxa Biotech AG Ordinary Shares | $263.02M | — | $1.11 | ▲ 0.91% | $1.04$27.36 |
| ADAG Adagene Inc. American Depositary Shares | $273.45M | — | $2.06 | ▼ 14.17% | $1.3$4.85 |
| EBS Emergent BioSolutions Inc. Common Stock | $273.98M | — | $6.38 | ▼ 11.14% | $4.36$14.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Eledon Pharmaceuticals To Present Phase 2 BESTOW Trial At American Society Of Nephrology Kidney Week 2026 Annual Meetingbenzinga · 10/5/2026
- Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual MeetingYahoo · 10/5/2026
- Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - SlideshowSeekingAlpha · 9/22/2026
- Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation SocietyYahoo · 9/22/2026
- Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation SocietyBenzinga · 9/22/2026
- Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026Benzinga · 9/22/2026
Insider Activity
Insider Actions →- Steven Perrin · July 31, 2026 · Grant152.4K
- David-Alexandre C. Gros · July 31, 2026 · Tax Withholding194.8K @ $3.38
- David-Alexandre C. Gros · July 31, 2026 · Grant354.5K
- Steven Perrin · July 31, 2026 · Tax Withholding72.1K @ $3.38
Institutional Ownership
March 31, 2026
- Total shares held
- 41.73M
- Total value held
- $126.07M
- Institutional holders
- 119
- Unknown6.29M
- Unknown4.38M
- Unknown3.56M
- Unknown3.29M
- Unknown2.46M
- Unknown1.88M
- Unknown1.79M
- Unknown1.77M
- Unknown1.64M
- Unknown1.42M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart
Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.
ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart. Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.